Definition, prevalence and pathophysiology
Coronary artery disease (CAD) is one of the important causes of cardiovascular morbidity and mortality globally, giving rise to more than 7 million deaths annually. 1 An increasing burden of CAD in India is a major cause of concern with angina being the leading manifestation. Stable coronary artery disease (SCAD) is characterised by episodes of transient central chest pain (angina pectoris), often triggered by exercise, emotion or other forms of stress, generally triggered by a reversible mismatch between myocardial oxygen demand and supply resulting in myocardial ischaemia or hypoxia. 2 A stabilised, frequently asymptomatic phase following an acute coronary syndrome (ACS) is also classified as SCAD. This definition of SCAD also encompasses vasospastic and microvascular angina under the common umbrella.
The common clinical presentation of SCAD is chronic stable angina. The underlying mechanisms may include atherogenesis and plaque formation in epicardial arteries, spasm of normal or plaque containing arteries, micro-vascular, or left ventricular dysfunction due to prior acute myocardial necrosis or ischaemic cardiomyopathy. 2 In addition to chest discomfort, dyspnoea, palpitations, syncope or fatigue may also be present and sometimes may be the only symptom. Classical angina and micro-vascular angina are difficult to differentiate owing to the fact that both are exercise induced. Vasospastic angina, on the other hand, occurs at rest and has preserved effort tolerance. As opposed to ACS, SCAD lesions are more fibrotic, have a small necrotic core and little or no overlying thrombus. 3 Besides, they do not display erosion or rupture of endothelial lining. 4 Vasospasm is mostly due to various vasoconstrictor stimuli acting on hyperreactive vascular smooth muscle cells, like cellular rho-kinase activity, abnormalities in adenosine triphosphate (ATP) sensitive potassium channels and/or membrane Na + -H + counter-current transport. 5 The diffuse distal spastic reaction usually underlies micro-vascular angina, while focal spasm is classically observed in variant angina. In the last three decades, the prevalence of CAD has increased from 1.1% to about 7.5% in the urban population and from 2.1% to 3.7% in the rural population. 6 Coronary artery disease tends to occur at a younger age in Indians with 50% of cardiovascular mortality occurring in individuals aged <50 years. 7, 8 The younger CAD patients have more extensive angiographic involvement contributed by genetic, metabolic, conventional and nonconventional risk factors. Although several risk factors have been suggested, smoking, dyslipidemia and hypertension remain the major risk factors in the younger CAD patients. 6 A need for developing practice standards for the management of stable CAD was perceived by experts across India. This document aims to assist physicians, particularly cardiologists, in clinical decision-making by delineating a gamut of commonly acceptable modalities for the diagnosis, management, and prevention of stable angina. The current management standards have defined practices that meet the needs of most patients in the Indian context. 7 A modified GRADE system was used to derive quality of evidence and grades of recommendations.
Diagnosis
The initial and important step in the management of stable angina is the diagnosis. A detailed clinical history of angina includes assessing magnitude, location, severity, duration and precipitating factors of angina. Presence of typical nature of the discomfort, precipitating factors and relieving factors should be suggestive angina. Taking the medical history of a patient is the foremost and most vital process. Indeed in most cases a clear diagnosis can be made based on the history alone of a patient. 9 Physical examination is required to corroborate and strengthen the diagnosis. 10 Besides history and physical examination, diagnosis of stable angina needs the supporting evidence from non-invasive investigations to confirm it and sometimes provide additional prognostic information. It has been demonstrated that there is an association between low haemoglobin concentration and increased mortality in patients with stable angina. 11, 12 Similarly, fasting blood glucose has a prognostic importance in patients with stable angina. 13, 14 Furthermore, a full lipid profile, renal, liver and thyroid function tests, a 12-lead electrocardiography (ECG), resting echocardiography and chest X-ray can be helpful in evaluating stable angina. 2 An elevated resting heart rate is also associated with poor prognosis in patients with SCAD. 15 Patients with resting heart rate !70 bpm (beats per minute) exhibit a higher risk of vascular events compared to patients with a heart rate <70 bpm. 16 Therefore, it is prudent to include heart rate determination as a part of the routine cardiac assessment.
Fractional flow reserve (FFR) is an evidence-based diagnostic test gradually gaining prognostic value. 17 In a meta-analysis noninvasive FFR demonstrated high diagnostic efficacy comparable with invasively measured FFR for the detection of ischaemia in stable patients with suspected or known CAD. 18 Therefore, in select patients FFR testing can be recommended if resources permit.
The diagnosis of microvascular angina can be done by a combination of various modalities. It can be diagnosed by normal coronary angiogram and the absence of epicardial coronary spasm at rest or during acetylcholine provocation. A coronary flow reserve <2.5 on adenosine-induced hyperemia, 19 data from positron emission tomography 20 and cardiac magnetic resonance 21 have been also used in diagnosis of micro-vascular angina. Similarly, vasospastic angina can be diagnosed by ECG and coronary arteriography showing epicardial coronary spasm at rest or during acetylcholine provocation. 2 Further, exercise stress test and Holter monitoring can be used to detect silent ischaemia. 
Management
Diverse risk factor distribution, across various geographical locations in India mandates implementation of aggressive strategies for risk factor control and prevention. An effective usage of primary and secondary prevention strategies is another important aspect of CVD prevention and control. Developing the clinical practice algorithms translates best evidence into best practice and promotes quality by reducing healthcare variations, refining diagnostic accuracy, promoting appropriate therapy, and preventing the use of ineffective or potentially harmful interventions.
The treatment of stable angina includes anti-anginal medication, medication to modify atherosclerosis and aggressive treatment of causative risk factors. All patients with SCAD require life-long supervised treatment. Overall, management strategy includes, lifestyle changes, pharmacological management and prevention of cardiovascular events (Fig. 1) , various revascularisation techniques and management considerations for special groups such as women, elderly, renal dysfunction and diabetic patients.
Lifestyle management and control of risk factors

Smoking
Tobacco smoking is one of the frequent causes of mortality; indeed smoking can result in at least 2.8-3.1 fold increase in the risk of CAD. 32 Passive smoking or second-hand smoke has been demonstrated to exhibit a positive association with CAD (RR 1.27; 95% CI 1.10-1.48) and has displayed a crucial impact on the prognosis of CVDs. 33 It is known that about 35-40% of tobacco consumption in India is in smokeless form, mostly chewing. 34 Similar to smoking, smokeless tobacco also has a strong association with myocardial infarction (MI) (RR 1.13 (95% confidence interval (CI) 1.06-1.21)) and stroke 1.40 (95% CI 1.28-1.54). 35 Abstaining from all forms smoking (direct and second-hand or passive smoking) is an important factor in the primary and secondary prevention of cardiac events and has become an essential part of lifestyle management. Nicotine replacement and sustained release bupropion (bupropion SR) are the potential treatments for smoking. Nicotine patches have been examined extensively in patients with SCAD and shown to be safe. 36 
Diet
Several studies show that specific and conscious modification of diet is an essential step towards attaining healthy diet, which could decrease diet-induced CV risk. Indeed, in a prospective cohort study, 31,546 high-risk individuals from 40 countries, higherquality diet decreased risk of recurrent CVD events among people !55 years of age with CVD or diabetes mellitus. 37 A Mediterranean diet, Dietary Approach to Stop Hypertension (DASH) diet, rich in fruits, vegetables, and low-fat dairy foods and with reduced saturated and total fat has demonstrated a reduction in blood pressure and is effective as a nutritional strategy for preventing CVD. 38 In the Indian context, a diet rich in fruits and vegetable has a positive association with the heart diseases. Indeed, a couple of studies have observed a significant protective effect of vegetable intake against CAD risk. 39 The effects of a low-carbohydrate diet have also been investigated in a meta-analysis and was found correlative of modest but significant weight loss. 40 Further, drinking plenty of water, 41 and reducing the consumption of sweetened beverages and juices 42 are advisable, as they can reduce the excessive body weight considerably. Consumption of alcoholic beverages has not been found to be beneficial in Indian patients and if at all should be limited to 2 glasses per day (20 g/day of alcohol) for men and 1 glass per day (10 g/day of alcohol) for nonpregnant women. Moreover, Omega-3 polyunsaturated fatty acids has a promising role in primary but particularly in the secondary prevention of CVD.
43,44
Physical activity
Regular physical activity and aerobic exercises have demonstrated decreased risk of fatal and non-fatal coronary events. 45 Moreover, a sedentary lifestyle is one of the key risk factors for CVD. 46 Therefore, occupational and leisure time physical activity can be recommended for the prevention of CVD. In this context, a meta-analysis of observational data demonstrated that high level occupational physical activity protected against ischaemic stroke compared with both moderate (RR = 0.77, 95% CI 0.60-0.98) and inactive occupational levels (RR = 0.57, 95% CI 0.43-0.77). 47 
Weight management
Overweight and obesity are the well-recognised risk factors for CAD. 48 The metabolic consequences of obesity such as dyslipidemia 50, 51 For Asian Indians, the WC cut-offs at action level 1 are: men, 78 cm; women, 72 cm; and the corresponding values at action level 2 are 90 cm and 80 cm for men and women, respectively. Any person attaining action level 1 should avoid gaining weight and maintain physical activity to avoid developing any of the cardiovascular risk factors. Similarly, action level 2 indicates need for medical advice. 50 
Lipid management
Dyslipidemia is one of the critical risk factors for CVD. 52 Dyslipidemia should be managed according to lipid management guidelines with pharmacological and lifestyle interventions. 53 Treatment objectives include LDL-cholesterol (LDL-C) below 1.8 mmol/L (<70 mg/dL) or >50% (LDL-C) reduction when an objective level cannot be reached. Patients having CAD are considered as highly vulnerable subjects for cardiovascular events and statin treatment should be considered as early as possible, regardless of LDL-C concentrations. Indeed, a meta-analysis demonstrated that statin pre-treatment in patients with stable angina reduces procedural myocardial necrosis and overall major adverse cardiac event. 54 Other interventions like fibrates, nicotinic acid, ezetimibe have also been examined for reducing cardiovascular events.
Diabetes mellitus
Comprehensive risk reduction is essential for the management of diabetic patients with CAD. General measures should comprise diet, physical activity, complete cessation of smoking, and weight and lipid profile management. Furthermore, pharmacological management for glycaemic control has its important role to achieve precise glycaemic control (objective HbA 1C < 7.0%). 
Arterial hypertension
Arterial hypertension is one of the risk factors for SCAD and other CVDs. 55 It is advisable to lower the systolic blood pressure (SBP) to <140 mmHg and diastolic blood pressure (DBP) to <90 mmHg in SCAD patients with hypertension. Moreover, diabetes patients are advised to achieve a goal of at least lower than 140/85 mmHg BP. 44 Recommendations on lifestyle management and risk factor modifications:
It 
Pharmacological management
The main objectives of the pharmacological management of SCAD include relief of anginal symptoms and to avert cardiovascular anginal episodes or cardiovascular event prevention.
Relief of anginal symptoms
Besides anti-ischaemic agents, other initiatives such as lifestyle changes, including regular physical exercise, and revascularisation may play a crucial role in symptom amelioration. In addition, patient education is vital to improving adherence to the measures of primary and secondary prevention in the course of disease management over the long tenure.
5.1.1. Long-term relief of symptoms 5.1.1.1. Beta-blockers. Beta-blockers improve oxygen supply and demand balance by reducing heart rate, myocardial contractility and after-load. Reduction in heart rate allows greater diastolic time with increased coronary perfusion that improves myocardial oxygen supply.
Though there is no direct evidence from placebo-controlled trials that demonstrate the benefits of beta-blockers in stable CAD patients in absence of prior MI, a meta-analysis has demonstrated that cardio-selective beta-blockers may improve mortality when compared with placebo. 73 The use of beta-blockers has certainly been found beneficial in relieving angina in the randomised trials enrolling post-MI or heart failure patients. Beta-blockers are also found to be effective in regulating exercise-induced angina, increasing exercise capacity and controlling both symptomatic as well as asymptomatic ischaemic attacks.
5.1.1.2. Calcium channel blockers. Calcium channel blockers (CCBs) noncompetitively inhibit calcium influx through voltage-dependent L-type calcium channels, resulting in negative inotropic effects, chronotropic effects, slowing conduction, and smooth muscle relaxation. CCBs are chemically of two types: dihydropyridine (DHP) CCBs and non-DHP CCBs. The non-DHP CCBs (verapamil and diltiazem), due to their sinus node inhibiting activity, reduce the heart rate and act as anti-anginal drugs. A meta-analysis revealed that when compared with placebo, CCBs resulted in a 28% reduction in the risk of heart failure (95% CI 0.73-0.92) in patients with CAD. 74 This meta-analysis also demonstrated that long-acting CCBs (either DHPs or non-DHPs) were associated with a decrease in the risk of stroke, angina pectoris and heart failure with similar outcomes for other cardiovascular events as the comparison. 74 5.1.1.3. Beta-blockers vs. calcium channel blockers. Beta-blockers have been compared to CCBs in numerous trials for the management of stable angina. With regard to the treatment efficacy against angina, beta-blockers and CCBs are found to be similar. [75] [76] [77] Indeed, a couple of meta-analyses revealed that the CCBs and beta-blockers exert similar anti-anginal effects;
nevertheless, beta-blockers were found to be associated with fewer adverse events than CCBs. 73, 78 5.1.1.4. Beta-blockers plus calcium channel blockers. Beta-blockers in combination with DHP-CCBs were found to be more effective in relieving angina. A meta-analysis based on effects on exercise testing concluded that the combination of a calcium antagonist and a beta-blocker was statistically more effective than either monotherapy. 79 The choice of the first-line agent should be individualised based on the desired pharmacological actions, co-morbidities and side effects. However, the use of beta-blockers in combination with diltiazem and verapamil should be avoided due to the probable risk of bradycardia.
2,80
5.1.1.5. Trimetazidine. Trimetazidine is a novel metabolic modulator. It inhibits reduction of intracellular ATP levels via conservation of cellular metabolism in ischaemic regions and stimulates myocardial glucose consumption through inhibition of fatty acid metabolism. 81 Eventually, it leads to the formation of ATP while consuming less oxygen (which is inadequate in ischaemia) without affecting heart rate, blood pressure and myocardial contractility.
82,83
The Trimetazidine European Multicenter Study compared the efficacy of trimetazidine with beta-blocker propranolol and found no difference between the two groups with regards to anginal attack rate per week, exercise duration or time to 1 mm STsegment depression. 84 A Cochrane systematic review (n = 23),
revealed that in comparison with placebo, trimetazidine alone or combined with conventional anti-anginal agents, decreased the number of weekly angina attacks (mean difference À1.44, 95% CI À2.10 to À0.79; p < 0.0001), reduced weekly nitroglycerin intake (95% CI À1.47 to À2.20, À0.73; p < 0.0001) and improved exercise time to 1 mm ST segment depression (p = 0.0002). 85 In a retrospective analysis assessing the independent effect of antianginal drugs on subsequent mortality risk in patients with stable angina, trimetazidine treatment was associated with significantly reduced risk of death after surviving an acute myocardial infarction (AMI). 86 Trimetazidine has been evaluated in diverse patient populations ranging from stable angina, post-MI, pre, post PCI and heart failure and was found to have excellent safety and tolerability profile without any known drug interactions. It was found to be safe when added to ongoing therapy with betablockers, CCBs, and nitrates, without unfavourable drug interactions in SCAD. 87 In fact, it has been shown that combining a metabolic agent with a haemodynamic agent may offer a better synergistic efficacy when compared to a combination of two haemodynamic agents. 88 In a recent systematic review and metaanalysis of AMI patients, adjunctive trimetazidine treatment was associated with a significant reduction of major adverse cardiac events (MACE) (OR = 0.33, 95% CI = 0.15-0.74; p = 0.007). 89 The usual dose of trimetazidine is 20 mg three times daily or sustained release 35 mg twice daily with meals. 90 The European Society of Cardiology (ESC) guidelines recommend the use of trimetazidine as a second-line treatment for the treatment of angina on the basis of current evidence. 2 However, use of trimetazidine in patients with
Parkinson's disease and motion disorders such as restless leg syndrome, tremor muscle rigidity and walking disorders, is contraindicated. 
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A systematic review demonstrated that in comparison to placebo, alone or in combination with other anti-anginal drugs (amlodipine and atenolol), ranolazine reduced anginal symptoms among patients with symptomatic chronic stable angina pectoris on traditional anti-anginal medications. 92 Ranolazine has been studied in several trials such as Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) study, 93 the Efficacy of Ranolazine in Chronic Angina (ERICA) trial 94 and the Combination Assessment of Ranolazine In Stable Angina (CARISA) study. 95 In the Metabolic Efficiency with Ranolazine for Less Ischaemia in Non-ST-Elevation Acute Coronary Syndromes (MERLIN-TIMI) trial involving 6560 patients with NSTE-ACS, ranolazine did not reduce the primary composite endpoint of cardiovascular death, MI or recurrent ischaemia. 96 In a more recent RIVER-PCI trial enrolling 2651 chronic angina patients with incomplete revascularisation post PCI, ranolazine had no effect on primary endpoint consisting of ischaemia driven revascularisation and hospitalisation without revascularisation (HR 0.95, 95% CI 0.82-1.10; p = 0.48). 97 Co-administration of ranolazine with cytochrome P3A (CYP3A) inhibitors like verapamil, diltiazem, macrolide antibiotics and grapefruit juice, should be monitored as these drugs may cause an increase of ranolazine levels in plasma. 91 Ranolazine clearance is reduced in renal and hepatic impairment. Ranolazine should be used cautiously with QT-prolonging drugs as it may increase QTc. 91 Ranolazine may be recommended as an adjunctive therapy in patients with chronic stable angina who are symptomatic despite the use of conventional treatment. The current ESC guidelines recommend ranolazine as a second-line treatment as it is devoid of any effects on heart rate, blood pressure and tolerance. 2 Ranolazine is well tolerated; the major adverse effects reported with ranolazine include constipation, nausea, dizziness, and headache. The effective recommended dose of ranolazine is 500 mg to 1000 mg twice daily.
5.1.1.7. Ivabradine. Ivabradine blocks the f channel in the sino-atrial node and inhibits the I f current, causing a specific heart rate reduction without affecting the force of contraction. This exclusive heart rate reduction helps in prolonging diastole and thereby improving myocardial oxygen balance. Further, ivabradine is devoid of any effect on blood pressure or myocardial contractility or conduction time. Ivabradine or ivabradine plus beta-blocker, when compared to placebo alone, produced dose-dependent improvements in exercise tolerance and time to development of ischaemia during exercise. 98, 99 When added to beta-blocker (atenolol), in the Morbidity-Mortality Evaluation of the I f inhibitor ivabradine in patients with coronary artery disease and left ventricular dysfunction (BEAUTIFUL) trial, ivabradine decreased the admission to hospital for fatal and non-fatal myocardial infarction and coronary revascularisation. It was noteworthy that the effects were more pronounced in patients with heart rate !70 bpm. 16 Ivabradine was found to be as effective as beta-blocker (atenolol) in increasing total exercise duration and reducing the number of anginal attacks. 100 Moreover, combining ivabradine with low dose beta-blocker (bisoprolol) vs. uptitration of beta-blocker in stable angina patients with left ventricular (LV) systolic dysfunction produced additional anti-anginal and anti-ischaemic benefits and improved chronotropic reserve and exercise tolerance. 101 Further, ivabradine was found to be as effective as CCB (amlodipine) in improving exercise tolerance and demonstrated superior reduction of myocardial oxygen consumption with similar safety. 102 Ivabradine has also displayed a good tolerability and anti-anginal efficacy in patients with chronic stable angina treated with concomitant anti-anginal medications (anti-thrombotic agents, lipid-lowering agents, long-acting nitrates and dihydropyridine CCBs). 103 Ivabradine is well tolerated and recommended at a dose of 5 and 7.5 mg twice daily for chronic stable angina and the maintenance dose should not exceed beyond 7.5 mg twice daily. Concomitant use of verapamil and diltiazem with ivabradine is contraindicated. 104 The current ESC-2013 guidelines recommend ivabradine as a second line therapy for symptom relief in stable coronary artery disease patients based on the available evidence.
2 5.1.1.8. Nicorandil. Nicorandil functions via activating ATP-sensitive potassium channels and promoting systemic venous and coronary vasodilatation, eventually it causes a rise in coronary blood flow, a decrease in after-load, preload and oxidative injury. 105 The efficacy of nicorandil in patients with stable angina has been compared to placebo, alone or in combination with standard anti-anginal medications in randomised trials, including the Impact Of Nicorandil in Angina (IONA) randomised study, 106 the Study of Women's health Across the Nation (SWAN) group study, 107 and some Asian studies. [108] [109] [110] A meta-analysis evaluating the short-term efficacy of nicorandil compared with antianginal drugs for stable angina found that nicorandil did not show a significant reduction of weekly angina frequency. Further, there were no significant differences in total exercise duration, time to 1-mm ST-segment depression, and time to onset of pain.
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Chronic use of nicorandil could stabilise coronary plaques in patients with stable angina. 112 Use of nicorandil may be associated with the side-effects such as oral, intestinal and peri-anal ulceration as well as frequent headaches. Concomitant use of nicorandil with sulphonylureas was an important exclusion criterion in the IONA trial since nicorandil and sulphonylureas compete and have opposite effects at potassium channels. 106 Presently, ESC-2013 guidelines recommend nicorandil as a second line therapy for symptom relief in stable coronary artery disease patients. 5.1.1.9. Nitrates. Nitrates can be effective in combating all forms of angina. Nitrates cause vascular smooth muscle relaxation resulting in both the coronary arteriolar and venous dilatation together leading to reduced preload. A meta-analysis assessed the effect of nitrates for stable angina and reported that long-term administration of nitrates was beneficial for angina prophylaxis and improved exercise performance. With continuous regimen, low-dose nitrates were more effective than high-dose for improving exercise performance. On the contrary, with the intermittent regimen, high-dose nitrates were more effective. 113 
Long-acting nitrates for angina prophylaxis
Long-acting nitrates are recommended for treating angina when additional therapy to control angina is necessary or if the initial therapy with a beta-blocker or non-DHP CCB is contraindicated or poorly tolerated. Tolerance to nitrates could develop if long-acting nitrates are regularly administered over a prolonged period (around 8-10 h). Moreover, exacerbation of endothelial dysfunction is a possible complication of long-acting nitrates.
A meta-analysis of trials comparing beta-blockers, CCBs, and nitrates for stable angina, found no significant differences in weekly anginal episodes, time to ST-segment depression, total exercise time, or sublingual nitroglycerin use when long-acting nitrates were compared to either beta-blocker or CCBs. 78 However,
it is important to note that only a few studies compared longacting nitrates with beta-blockers or CCBs. In agreement with these results, the current NICE guidelines also find poor quality of evidence for the use of long-acting nitrates in combination with beta-blockers in patients with stable angina. 114 Often oral administration of isosorbide dinitrate can be used for angina prophylaxis. In a placebo-controlled clinical study, duration of exercise increased substantially for around 6-8 h upon a single dose (15-120 mg) of oral isosorbide dinitrate; but the effect was sustained for only 2 h when similar doses were administered repeatedly for 4 times daily. 115 Similarly, extended-release formulation of isosorbide dinitrate was also found to be nonsuperior to placebo in a large multicenter clinical study. Therefore, presently the use of isosorbide dinitrate is not evidence-based. Moreover, mono-nitrates also exhibit similar complications.
116,117
5.1.3. Short-acting nitrates for acute angina Fast acting formulations of nitroglycerin can show immediate relief from angina. They can be employed in cases where the anginal episode has just started or when the symptoms are likely to appear (such as activity after a meal, emotional stress, sexual activity and in colder weather). During the course of anginal attacks, the patient should be advised to attain sitting position and self-administer sublingual nitroglycerin (0.3-0.6 mg) for every 5 min until the pain is relieved or a maximum of 1.2 mg is used (within 15 min). 2 In summary, the level of evidence for emerging therapies such as trimetazidine, ranolazine, nicorandil and ivabradine is similar to the older drugs like beta-blockers and CCBs. The only difference is the widespread availability of the older drugs. However, considering similar efficacy in prognosis and symptom relief, it is recommended to individualise patient treatment according to their characteristics, co-morbidities, and contraindications. 118, 119 Emerging therapies are certainly effective 2nd line agents when angina is not relieved by conventional drugs.
Recommendations on relief of angina symptoms: The addition of long-acting nitrates, trimetazidine, ivabradine, ranolazine or nicorandil is proposed in case of intolerance or contraindications or failure in achieving control by beta-blockers and/or CCBs. The choice of the drug should be made on the basis of blood pressure, heart rate and tolerance. [Grade A, Evidence 2] 98, 100, 106, 114, 115, 117, 125, 126 Ivabradine may be considered in symptomatic patients who do not tolerate beta-blockers or in whom the resting heart rate remains above 70 bpm, despite administration of the full tolerable dose of beta-blockers. [Grade A, Evidence 2] 16,100,101
When two haemodynamically acting drugs fail to achieve the desired results in reducing angina, preference may be given to cardio-metabolic agents like trimetazidine or ranolazine as they have a different mode of action and may offer better efficacy in combination with a haemodynamic agent. [Grade A, Evidence 2] 87,88
Event prevention
The measures to stop myocardial ischaemia and CVD related deaths, chiefly focus on decreasing the occurrence of acute thrombotic events and preventing ventricular dysfunction. These objectives can be attained by pharmacological or lifestyle approaches which may modify the natural history by diminishing progression or regression of plaques, stabilising plaques by decreasing inflammation and thus preventing plaque rupture and thrombosis.
5.1.4.1. Anti-platelet agents. Anti-platelet drugs reduce platelet accumulation and prevent the development of thrombus. Among anti-platelet drugs, low-dose of aspirin or clopidogrel are the most common agents used. While considering effectiveness, safety and cost issues, low-dose aspirin is the choice of anti-platelet drug in many cases.
Low-dose of aspirin: Aspirin is an important drug for prevention of arterial thrombosis. It functions by inhibiting platelet cyclooxygenase-1 (COX-1) irreversibly and eventual thromboxane production. Considering effectiveness and safety, aspirin 75 mg daily dose is recommended for all patients with stable angina.
A meta-analysis reviewed the usage of low-dose of aspirin in patients with SCAD and found that aspirin reduces all-cause mortality, adverse cardiovascular events, nonfatal MI, and nonfatal stroke. However, aspirin increases the risk of major bleeding. Moreover, no additional beneficial effects were seen with a higher dose of aspirin (300 mg vs. 50-100 mg/d). 127 The beneficial effects of aspirin are attained within the dose range of about 75-150 mg/ day; more precisely the ideal anti-thrombotic activity of aspirin was found to be at 75-80 mg/day. Aspirin, when used in larger doses can precipitate gastrointestinal side-effects.
128-131
Clopidogrel: Clopidogrel inhibits platelet accumulation by selective and irreversible inhibition of adenosine diphosphate P2Y12 receptor. Clopidogrel 75 mg daily can be recommended in patients who are intolerant to aspirin. This is backed by Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study. The study compared clopidogrel (75 mg) with aspirin (325 mg) in subjects with previous MI, stroke, or symptomatic peripheral artery disease (PAD). 132 The findings of CAPRIE study demonstrated the superiority of clopidogrel over aspirin in reducing the combined risk of ischaemic stroke, MI, or vascular death; however, the extent of difference was small. Overall safety profile of clopidogrel was at least as good as that of medium-dose aspirin. 132 Clopidogrel is mainly metabolised by cytochrome P450, CYP2C19 variant. Other drugs, such as proton pump inhibitors (PPIs) and statins that are metabolised by CYP2C19 can competitively inhibit the enzyme and impair metabolism of clopidogrel. 133 Additionally, a study compared clopidogrel with aspirin plus esomeprazole (PPI) for the prevention of recurrent bleeding from ulcers in high-risk patients and found that the combination of aspirin plus esomeprazole was superior to clopidogrel. 134 Therefore, in patients who have gastrointestinal bleeding while on aspirin, adding a PPI could be more effective than using clopidogrel instead of aspirin.
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Prasugrel and ticagrelor are newer P2Y12 inhibitors that demonstrate better platelet inhibition, when compared to clopidogrel. 135, 136 Both prasugrel and ticagrelor have exhibited a marked decrease of cardiovascular outcomes when compared to clopidogrel in patients with ACS. However, the clinical benefits of these drugs have not been demonstrated in SCAD patients and therefore cannot be currently recommended for use in these patients.
137,138
5.1.4.2. Combination of anti-platelet agents. Combinations of antiplatelet agents are currently not routinely recommended for SCAD. In a Cochrane systematic review, the use of clopidogrel plus aspirin, compared with placebo plus aspirin, was associated with a lower risk of cardiovascular events (OR: 0.87, 95% CI 0.81-0.94; p < 0.01) and a higher risk of major bleeding (OR 1.34, 95% CI 1.14-1.57; p < 0.01). The review concluded that dual anti-platelet therapy is not advisable for routine management of SCAD, except in patients after stenting, where benefits outweigh harm. 139 Furthermore, adding an antagonist of protease activated receptor type 1 (PAR-1), vorapaxar to standard anti-platelet therapy in patients with stable atherosclerosis displayed a significant decrease in cardiovascular death, MI or stroke. The beneficial effects were more prominent in the post-MI group of patients. 140 However, vorapaxar caused an increase in the risk of moderate or severe bleeding. 140, 141 In summary, combined antiplatelet therapy may be advised only in select SCAD patients at high risk of ischaemic events.
5.1.4.3. Renin-angiotensin-aldosterone system modulators. The renin-angiotensin-aldosterone system plays a vital role in maintaining haemodynamic stability through regulation of arterial blood pressure, water and electrolyte balance. 142 Angiotensinconverting-enzyme inhibitors (ACEIs) prevent the conversion of angiotensin I to angiotensin II and that eventually prevents the effects of angiotensin II, such as narrowing of blood vessels and raising blood pressure. Furthermore, ACE inhibition eventually prevents the degradation of bradykinin, hence promotes vasodilatation and corrects endothelial dysfunction. Moreover, it is important to note that angiotensin II receptor blockers (ARBs) are devoid of such bradykinin related actions.
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The beneficial effect of ACEI, ramipril at a target dose of 10 mg daily at night was examined in the HOPE (Heart Outcomes Prevention Evaluation) study that enrolled the patients with high risk for cardiovascular events and devoid of LV dysfunction and heart failure. The study demonstrated that ramipril compared to placebo, considerably (p < 0.001) reduced the primary composite endpoints of cardiovascular death (ramipril [6.1%] vs. placebo [8.1%]), AMI (9.9% vs. 12.3%), and stroke (3.4% vs. 4.9%). 144 In contrast to the HOPE study conducted in high-risk patients, the EUROPA (EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease) study done in documented CAD patients, who were optimally protected with aspirin, beta-blockers and statins, confirmed the benefits of ACE inhibitor perindopril in all CAD patients; whether low, medium or high risk CAD patients. 144, 145 Together, the HOPE and EUROPA studies provide strong evidence that patients with SCAD, vascular disease, and diabetes (with one further high-risk factor), regardless of LV function should be considered for treatment with either of these two ACE inhibitors. 146 Further, in a meta-analysis of ACEI therapy compared with placebo in patients (n = 31,555) with CAD and preserved LV systolic function, ACEI therapy demonstrated a reduction in cardiovascular mortality (RR 0.83, 95% CI 0.72-0.96, p = 0.01), non-fatal MI (RR 0.84, 95% CI 0.75-0.94, p = 0.003), all-cause mortality (RR 0.87, 95% CI 0.81-0.94, p = 0.0003) and revascularisation rates (RR 0.93, 95% CI 0.87-1.00, p = 0.04). 147 In the EUROPA-CCB post hoc analysis, perindopril given on top of amlodipine significantly reduced total mortality by 46% (p < 0.01) and primary end point (composite of cardiovascularmortality, non-fatal MI and resuscitated cardiac arrest) by 35% (p < 0.05) and provided a significant supplementary impact. 149 Furthermore, the Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial compared the effectiveness of benazepril plus amlodipine with benazepril plus hydrochlorothiazide. In this study, combination therapy with benazepril and amlodipine exhibited an excellent blood-pressure control and a clear benefit with respect to cardiovascular outcomes. 150 In view of these findings, the combination of amlodipine and an ACE inhibitor seems to be a better alternative in SCAD patients with hypertension.
Combination of angiotensin II receptor blocker (ARB) with angiotensin-converting-enzyme inhibitors (ACEI) vs. ARB alone
The ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) -study examined the effect of ACE inhibitor ramipril, ARB telmisartan and their combination in patients with vascular disease or high-risk diabetes. The results demonstrated non-inferiority of telmisartan with primary outcome (death from cardiovascular causes, MI, stroke, or hospitalisation for heart failure) occurring in 16.5% and 16.7% patients of ramipril group and telmisartan group, respectively (relative risk (RR), 1.01; 95% CI 0.94-1.09). In the combination therapy group, the primary outcome occurred in 16.3% patients (RR, 0.99; 95% CI 0.92-1.07) and as compared to the ramipril group, there was an increased risk of hypotension (4.8% vs. 1.7%, p < 0.001), syncope (0.3% vs. 0.2%, p = 0.03), and renal dysfunction (13.5% vs. 10.2%, p < 0.001). It is noteworthy that the findings of this study could not be generalised to say ACEIs and ARBs are similar. 151 A previous meta-analysis inferred that ARBs are indeed inferior to ACEIs with respect to major cardiovascular events like MI and cardiovascular death. 152 Further, the metaanalysis stated that when clinicians have to choose either an ACEI or an ARB in high-risk patients, they should be cognizant of the unique differences between each class of medications, particularly with respect to MI and cardiovascular death. 152 ACEIs should be the first choice across the spectrum of cardio-metabolic risk reduction. A combination of ACEI and ARB therapy should be avoided. ARBs can be considered as an alternative therapy for patients with SCAD when ACE inhibitors are not tolerated. 155 Moreover, meta-analysis of cardiovascular outcomes trials comparing intensive vs. moderate statin therapy, reported a significant 16% reduction in coronary death or MI (p < 0.00001), as well as a significant 16% reduction of coronary death or any cardiovascular event (p < 0.00001). 156 Hence, statin in high intensity (or at least moderate intensity) should be prescribed in all patients with SCAD irrespective of lipid levels.
Beta-blockers.
There are no confirmatory trials of the beneficial effects of beta-blockers in SCAD patients. Indeed, the anticipated beneficial effects of beta-blockers in SCAD patients are eventual extrapolations from the studies in the patients with MI and patients with new-onset of CHD. 157 However, in the international REACH registry, beta-blockers use couldn't lower event rate of cardiovascular events at 44-month follow-up, even among patients with prior history of MI. 158 Moreover, a metaanalysis of randomised studies involving MI patients concluded that b-blockers have no mortality benefit but reduce recurrent MI and angina (short-term). 159 In summary, at present, studies are warranted for the use of b-blockers in event prevention in SCAD patients.
Other anti-anginal agents and event reduction.
A few other drugs such as trimetazidine, nicorandil, ivabradine and ranolazine also have been examined for prevention of cardiovascular events in patients with stable angina. The Impact Of Nicorandil in Angina (IONA) study in patients with stable angina found a significant difference in achieving primary endpoint (coronary heart disease death, non-fatal MI, or unplanned hospital admission for cardiac chest pain, HR 0.83, 95% CI 0.72-0.97; p = 0.014) by nicorandil therapy. However, it could not attain the secondary endpoint (combined outcome of coronary heart disease death or non-fatal MI, HR 0.79, 95% CI 0.61-1.02; p = 0.068). 106 In addition, the Metabolic Efficiency with Ranolazine for Less Ischaemia in Non-ST-Elevation Acute Coronary Syndromes (MERLIN)-TIMI 36 trial observed that addition of ranolazine to standard treatment for ACS was not effective in reducing major cardiovascular events. However, ranolazine did not adversely affect the risk of all-cause death or symptomatic documented arrhythmia. 160 The morBidity-mortality EvAlUation of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTI-FUL) study, found no effect of ivabradine on the primary composite endpoint (cardiovascular death, admission to hospital due to AMI, and admission to hospital for new onset or worsening heart failure) (HR 1.00, 95% CI 0.91-1.1, p = 0.94). 161 However, it reduced secondary endpoints: admission to hospital for fatal and non-fatal MI (0.64, 95% CI 0.49-0.84, p = 0.001) and coronary revascularisation (0.70, 95% CI 0.52-0.93, p = 0.016) in a prespecified subgroup of patients with heart rate of 70 bpm or greater. Based on this, ivabradine could be used in a subgroup of patients who have elevated heart rate (!70 bpm). Similarly, the Study assessInG the morbidity-mortality beNefits of the If Inhibitor ivabradine in patients with coronary arterY disease (SIGNIFY) found that ivabradine, added to guideline-recommended medical therapy, did not improve the outcome in patients who had SCAD without clinical heart failure. 162 However, BEAUTIFUL and SIGNIFY varied in terms of patient population and dose of ivabradine, which might have led to different clinical outcomes. 162 A preliminary study, METRO (ManagEment of angina: a reTRospectivecOhort) found that inclusion of trimetazidine in the anti-anginal treatment of stable angina is independently associated with a significant reduction in mortality after surviving an MI. 86 5.1.5.4. Chelation therapy. Chelation therapy includes a series of intravenous infusions of disodium ethylene diamine tetraacetic acid (EDTA) in combination with other substances. It has been suggested that EDTA chelation therapy can result in relief of angina in patients with stable ischaemic heart disease. 163 A few earlier clinical studies could not confirm positive effects of chelation therapy. However, recently the Trial to Assess Chelation Therapy (TACT) was conducted in subjects with CAD and found reduction in the risk of cardiovascular events by 18% (HR = 0.82; 95% CI 0.69-0.99; p = 0.035). 164 Nevertheless, additional studies are needed to confirm the utility of chelation therapy. 6. Treatment of certain forms of stable CAD
Silent myocardial ischaemia
Silent myocardial ischaemia is defined as objective evidence of myocardial ischaemia in the absence of chest discomfort or other anginal equivalents. Myocardial ischaemia either silent or symptomatic, generally results from increased oxygen demand or reduced blood supply and/or the combination of both. Therefore, the treatment modalities should address both supply and demand.
Studies have examined whether pharmacological interventions could ameliorate silent ischaemia. Medical therapy has been also compared with revascularisation in silent ischemia patients.
Silent myocardial ischemia should be treated like asymptomatic CAD. Mangement of silent ischaemia should include aspirin, statin, combined with beta-blockers, nitrates, CCBs. The use of metabolic modulators mainly trimetazidine and ranolazine have also been examined. In a study, administration of trimetazidine to diabetic patients receiving standard anti-anginal therapy exhibited a significant reduction of silent myocardial ischaemic episodes and the total silent ischaemic burden compared with placebo. 170 Furthermore, trimetazidine (70 mg/day and 140 mg/day) in symptomatic and asymptomatic patients with chronic ischaemia receiving background beta-blockers, was found to ameliorate effort-induced myocardial ischaemia and functional capacity. 171 In addition, in a study comparing the efficacy of lacidipine, bisoprolol and trimetazidine, only trimetazidine was found to reduce the late afternoon peak transient ischaemic episodes. 172 Further in a study, in CAD patients with diabetes mellitus, trimetazidine treatment was found to show significant improvement (p = 0.009) in silent myocardial ischaemia. 173 Similarly,
another study compared the efficacy of diltiazem and trimetazidine, in patients suffering from silent myocardial ischaemia, after CABG surgery. Trimetazidine and diltiazem were effective in reducing silent myocardial ischaemia following CABG. Moreover, trimetazidine found to be superior to diltiazem at 6 months on 24-hr ambulatory ECG monitoring and myocardial scintigraphy. 174 Recently a phase II study revealed that lowering of heart rate with ivabradine can result in reduction or resolution of silent ambulatory myocardial ischaemia (SAMI) recorded as episodes of ST-segment depression in ambulatory monitoring of the ECG. However, a larger study is required to confirm these results and to demonstrate the effect of SAMI reduction on long-term mortality of chronic ischaemic heart disease. 175 Another study examined the efficacy of ranolazine in patients of atrial fibrillation (AF) with CAD 176, 177 ; (a major proportion of AF episodes were asymptomatic in nature). Ranolazine demonstrated shorter total AF duration (81.56 AE 45.24 h vs. 68.71 AE 34.84 h, p = 0.002), decreased AF burden (1.89 AE 1.05% vs. 1.59 AE 0.81%, p = 0.002), and shortened mean AF duration (1.15 AE 0.41 h vs. 0.92 AE 0.35 h, p = 0.01). 176, 177 However, specific studies are needed address the efficacy of ranolazine in silent ischaemia. 178, 179 Recommendations for management of silent angina:
Silent myocardial ischaemia should be managed like asymptomatic CAD and may need administration of anti-ischaemic therapy and revascularisation as required. 
Microvascular angina
Microvascular angina can be described as angina pectoris caused by anomalies of small coronary arteries. The main objective of medical therapy of micro-vascular angina is to control the symptoms and improve the quality of life because there is inadequate information about its causes and risk factors.
Initial therapy can be started with the classical anti-ischaemic agents. 180 For symptomatic relief of angina, short-acting nitrates can be prescribed. Use of beta-blockers is an appropriate choice, especially in the patients with increased activity of the adrenergic system. Propranolol, as well as atenolol, demonstrated a decrease in anginal attacks and ischaemic burden. Indeed, atenolol exhibited more efficiency than nitrates and CCBs. 181, 182 Further, nebivolol was found to increase nitric oxide release from vascular endothelium and significantly improve coronary flow. 183 However, the activity of beta-blockers has been disparate and fluctuated between 19% and 60%; requiring further therapeutic approaches. 184 Calcium channel blockers and nitrates were also associated with variable effects. Nisoldipine and sublingual nifedipine reduced ischaemic burden and improved anginal symptoms while diltiazem and verapamil failed to show any beneficial effects. 180, 185 These agents can be added to betablockers in case of inadequate control of symptoms. 186, 187 Further, the metabolic modulator, trimetazidine has been examined in two studies in patients with exercise-induced ischaemia and normal coronary arteries. These studies demonstrated that trimetazidine augmented exercise capacity and reduced angina frequency. 188, 189 Similarly, ivabradine has been examined for micro-vascular angina. In a recent study, a four-week treatment with ivabradine (5 mg twice daily) or ranolazine (375 mg twice daily) in addition to the standard anti-anginal therapy improved symptoms in patient with micro-vascular angina without affecting coronary flow reserve and endothelial function. 190 In another study, a 4-week treatment of ranolazine exhibited improvement in anginal symptoms and myocardial ischaemia in women with micro-vascular angina. 191 Recommendations on management of microvascular angina:
Micro-vascular angina patients can be initially treated with beta-blockers in addition to secondary preventive agents including aspirin and statins. 
Vasospastic angina
Vasospastic angina is a form of angina resulting from coronary artery spasm, which comprises of a sudden obstructive vasoconstriction of a part of an epicardial artery, manifesting into a decrease in coronary blood flow. 192 The clinical feature is dominated by rest angina, preserved effort tolerance and ST segment elevation in the ECG. In general, vasospastic angina responds to CCBs. 193, 194 A meta-analysis evaluating the efficacy of CCBs (amlodipine, nifedipine, benidipine and diltiazem) on vasospastic angina revealed that benidipine showed a statistically significant reduction in major cardiovascular events than amlodipine, nifedipine or diltiazem. 194 Further, long-acting nitrates can also improve the efficacy of treatment and should be scheduled to cover the period of the day in which ischaemic episodes most frequently occur, to prevent nitrate tolerance. 193 Beta-blockers should be avoided, to prevent probable spasm. 193 Furthermore, in refractive attacks of vasospastic angina, anti-alpha-adrenergic drugs, such as guanethidine or clonidine, may be helpful. 195 (The management of silent, micro-vascular and vasospastic angina is outlined in Fig. 2 ).
Recommendations for management of vasospastic angina:
The treatment of vasospastic angina should be individualised according to the diagnosis of each case. In patients who continue to be symptomatic, agents like trimetazidine, nicorandil, ranolazine and ivabradine may be effective.
[Grade A, Evidence 3] 188-190
Revascularisation
Coronary revascularisation is a process of restoring perfusion to ischaemic myocardium. Revascularisation in patients with SCAD is mandated whenever medical treatment does not improve prognosis or relieve symptoms. 2 The need for revascularisation in a SCAD patient is based on the presence of significant obstructive coronary artery stenosis, the degree of related ischaemia and the expected advantage to prognosis and/or symptoms. The dual purpose of revascularisation being: to improve survival and relieve symptoms. Further, the decision to revascularise is also based not only on symptom status but also the individual risk of procedure in the given patient. Revascularisation can be opted early when highrisk features are recognised in non-invasive test findings. 10 In view of unreliable findings on non-invasive examination revascularisation should not be considered without invasive findings of critical or multi-vessel disease. 198 Cardiac computed tomography angiography is sometimes used before proceeding to invasive angiography; however this practice remains controversial. 10 Further, invasive angiography is suitable and a necessary requirement for selecting the best revascularisation modality, even with the concomitant optimisation of medical therapy. There could be several factors such as clinical, anatomical and associated co-morbidities to be taken into account while considering revascularisation for a patient. Based on combination of clinical factors it may be difficult to arrive at a decision in a given patient. In such situations, a clinical decision should be made after consulting and discussing with an expert heart team in the clinical setting.
Several meta-analyses reveal that revascularisation may alleviate myocardial ischaemia more efficiently than medical treatment alone. 199, 200 Coronary revascularisation involves two modalities, one is the PCI and the other is CABG.
Percutaneous coronary intervention
The clinical efficiency of PCI in combination with medical therapy in SCAD patients has been examined in several clinical studies 201, 202 and reviewed in several meta-analyses. 203 208 Another meta-analysis compared the effect of PCI and medical therapy with medical therapy alone in patients with SCAD and objectively documented myocardial ischaemia; the review found that there were no differences between PCI and medical treatment in terms of death, MI, unplanned revascularisation or angina during a median followup of five years. 199 Further, PCI with drug-eluting stents (DES) compared with bare-metal stents (BMS) was compared in few studies. A metaanalysis revealed that risks of mortality associated with drugeluting and bare-metal stents are comparable. Sirolimus-eluting stents were found to be clinically better than bare-metal and paclitaxel-eluting stents. 209 A recent meta-analysis found that DES are highly effective in decreasing the risk of target-vessel revascularisation without an increase in any safety outcomes, including stent thrombosis. However, among the DES generations there were significant differences, such that everolimus-eluting stent (EES), sirolimus-eluting stent (SES), and zotarolimus-eluting stent-Resolute (ZES)-R were the most efficacious and EES was the safest stent. 210, 211 7.1.1. Coronary artery bypass grafting Usage of CABG for specific subsets of SCAD patients was compared with medical therapy in a meta-analysis. The analysis showed that The CABG group had significantly lower mortality than the medical treatment group at 5 years (10. 212 Similar findings were seen in other meta-analyses too. 200, 204 Further, the Medicine, Angioplasty, or Surgery Study (MASS II) compared effects of PCI, CABG and medical treatment in patients with multi-vessel CAD, stable angina, and preserved ventricular function. In this study, compared with CABG, medical therapy demonstrated a significantly higher incidence of subsequent MI, a higher rate of additional revascularisation, a higher incidence of cardiac death, and consequently, a 2.29-fold increased risk of combined events. Similarly, PCI exhibited a recurring need for further revascularisation, a higher incidence of MI, and a 1.46-fold increased risk of combined events compared with CABG. Furthermore, CABG was better than medical therapy at eliminating anginal symptoms. Moreover, several studies compared PCI and CABG and found that neither of them could demonstrate effectiveness for the full spectrum of SCAD patients who require revascularisation. 213 Nevertheless, CABG demonstrated a more complete revascularisation than PCI. Revascularisation is in itself a very broad topic for which separate guidelines are already available. The detailed evaluation of PCI or CABG is out of scope; thus in this document only the recommendations on indications for revascularisation have been given.
Recommendations on revascularisation:
The decision of considering revascularisation in patient with SCAD should be individualised. including those related to pregnancy and autoimmune diseases. Coronary artery disease starts appearing 5-10 years later in women as compared to men. 2 Women are more prone to CAD than men; however, its detection could be hindered by coronary artery positive remodelling. Indeed, the intravascular ultrasound substudy within the Women's Ischemia Syndrome Evaluation (WISE) demonstrated that, in a sample of 100 women with normal coronary arteries, %80% had definite coronary atherosclerosis that was concealed by positive remodelling. 214 These findings emphasise the need for better diagnostic and treatment modalities for women with concealed CAD. Until adequate evidence is presented, women with chest pain should be screened for CVD risk factors and treated accordingly. 44 
Patients with diabetes
Mortality due to CVD is amplified three-fold in diabetic men and two to five-fold in diabetic women, compared with the age and sexmatched non-diabetic persons. 2 The treatment of CAD in diabetic patients presents a challenge. Probable approaches for ideal care of patients with CAD and diabetes include the stringent and constant regulation of blood glucose and control of other risk factors such as dyslipidemia, renal disease, overweight and smoking. The classical anti-anginal interventions such as nitrates, betablockers, CCBs, statins, anti-platelet drugs and coronary revascularisation procedure have similar indications in diabetic and nondiabetic patients. Furthermore, in patients with coronary or other vascular disease or with diabetes, ACEIs were found to reduce rates of death from cardiovascular causes or AMI when compared with placebo. Therefore, ACE inhibitors can be the ideal choice in case of stable angina patients who also suffer from diabetes. 146, 215 Moreover, emerging therapies such as trimetazidine 85 and nicorandil 216 have shown beneficial effects in stable angina patients with diabetes. In diabetic patients with documented multi-vessel CAD and cardiomyopathy, trimetazidine as compared to control group significantly improved systolic wall thickening (1.7 AE 0.9 vs. 2.3 AE 0.9; p < 0.05), ejection fraction (43 AE 6% vs. 38 AE 6%; p = 0.007) and exercise duration (440 AE 140 s to 530 AE 145 s; p < 0.05). 85 Additionally, achieving a goal of HbA1C < 7.0% and blood pressure < 140/85 mmHg can be beneficial for the prevention of diseases progression in patients with diabetes and SCAD. 2, 217 In diabetic hypertensive's, PreterAx and DiamicroN Controlled Evaluation (ADVANCE) trial blood pressure-lowering arm revealed that a fixed combination of perindopril + indapamide significantly reduced total mortality by 14%, risk of cardiovascular death by 18% along with a significant 14% reduction in total coronary events and a 21% reduction in renal event. 218, 219 In fact, ADVANCE-ON is the first study ever to demonstrate sustained post-trial benefits of blood pressure lowering therapy on cardiovascular and total mortality in patients with type 2 diabetes. 220 There is now greater awareness regarding drug treatment strategy to achieve optimal glycemic goal but with cardiovascular safety, in type 2 diabetes. Metformin remains an ideal 1st line agent and amongst the sulphonylureas (SUs), the relative safety of a gliclazide makes it a preferred SU.
221-223 Latest Braunwald's text book of cardiology refers to the cardiovascular safety of gliclazide. 224 In addition, empagliflozin, an SGLT2 inhibitor has been examined in EMPA-REG OUTCOME trial; the study found that as compared with placebo, empagliflozin had a lower rate of the primary composite cardiovascular outcome and of death from any cause on the top of standard care. Therefore, empagliflozin can be useful in patients with type 2 diabetes who are at high risk for cardiovascular events. 225 Coronary artery revascularisation in diabetes remains a potential challenge. A study by Frye and co-workers revealed that there was no significant difference in the rates of death and major cardiovascular events among patients undergoing prompt revascularisation and those undergoing medical therapy in patients with diabetes and CAD. 226 Moreover, the choice of either PCI or CABG for revascularisation must be based on both anatomical and clinical factors. 2 A meta-analysis observed survival advantage for CABG over PCI in diabetic patients. 203 Another meta-analysis confirmed that revascularisation of patients with diabetes and multi-vessel disease by CABG decreased long-term mortality by about one-third compared with PCI using either BMS or DES. 227 A recent patient-level pooled analysis of three clinical studies found that CABG plus optimal medical therapy decreased the primary endpoint (composite of death, myocardial infarction (MI), or stroke) during long-term follow-up in patients with type 2 diabetes and stable CAD, making this as the ideal treatment strategy. 
Elderly patients
Data based on Randomized Controlled Trials (RCTs) to guide therapy in elderly patients are relatively scarce because of the common omission of elderly patients from most clinical trials. In elderly patients, diagnosis of angina would be difficult due to atypical symptoms and difficulties in performing stress testing. 232, 233 Elderly SCAD patients may generally suffer from other serious co-morbidities. Thus personalised discussion about goals of treatments, risk and benefit of therapeutic approaches, especially revascularisation of obstructive CAD by either PCI or CABG surgery, is important. Patient's choice can differ as a function of age. In elderly patients, the medical therapy is as effective as in younger patients, in terms of benefit and risk ratio. 234, 235 However, adverse effects, intolerance of anti-anginal agents are common. 236 Selection of anti-anginal drugs for elderly patients should be customised according to co-morbidities, contra-indications, adverse effects, costs, and personal choice. 237 Moreover, annual influenza vaccination can have beneficial effects in elderly SCAD patients. [238] [239] [240] The decision of opting for revascularisation is more challenging in elderly patients. Age may influence greatly the choice of revascularisation, especially in the patients with multi-vessel disease and/or left main stenosis. The TIME (Trial of Invasive versus Medical therapy in Elderly patients) study, which randomised patients with SCAD despite standard therapy, to an invasive vs. standard medical therapy, revealed that patients aged !75 years benefited from revascularisation over standard medical therapy in terms of symptom relief and quality of life (QOL). 241 Moreover, the invasive treatment was associated with a small early intervention risk, while medical treatment was associated with nearly 50% chance for later hospitalisations and revascularisations for increasing or refractory symptoms. Although 1-year outcomes in terms of mortality, symptom status and QOL were similar in both the groups, after 4 years, non-fatal events happened more often in standard medical therapy patients and survival was better for patients who were revascularised within the first year. 236, 242 Elderly women differed from men in disease presentation, perception and outcome. Despite similar angina at baseline and lower disease severity they had a lower QOL and worse survival. 243 Therefore, the choice of modality for managing SCAD in elderly patients should be individualised based on all the prognostic factors.
Recommendations on management of elderly SCAD patients:
The management of SCAD in elderly patients should be individualised based on all the prognostic factors. 
The patients after revascularisation
Secondary prevention and cardiac rehabilitation are essential parts of chronic management after revascularisation because such procedures decrease future morbidity and mortality. 244, 245 Compliance to lifestyle and risk factor adjustment requires personalised behavioural education and can be implemented during exercise-based cardiac rehabilitation. Education should be interactive, with full participation of patient care providers, providing an explanation for each intervention, while early mobilisation and physical conditioning should vary according to individual clinical status. 244, 245 Further, follow-up approaches should focus on the assessment of the patient's symptoms, functional status and secondary prevention, and not rely only on the detection of restenosis or graft occlusion.
Repeat revascularisation of the patient with prior coronary artery bypass graft revascularisation
Patients with prior revascularisation may present with recurence of anginal symptoms (as SCAD). Therapeutic option of repeat revascularisation is to be considered if symptoms persist despite optimal medical management. [246] [247] [248] The factors to be considered while deciding modality of the repeat revascularisation include the age of patients, co-morbidities and diffuseness of coronary disease, as well as the potential for damage to patent grafts, intra-luminal embolisation in saphenous vein grafts, lack of suitable arterial and venous conduits and instability of a graftindependent circulation. Generally, PCI is ideal modality for the patients with distinct lesions in grafts and preserved LV function or accessible native vessel disease. Repetition of bypass surgery may be required when the target vessels are inappropriate for PCI and when there are good distal vessel targets for bypass graft placement. The use of distal embolic protection devices is recommended in saphenous vein graft interventions. Any type of revascularisation modality should be accompanied with medical therapy with anti-anginal drugs and decreasing risk factors. 2 
Chronic total occlusions
Chronic total occlusions (CTO) are found in 15-30% of all the patients recommended for coronary angiography. [249] [250] [251] Chronic total occlusions denote the most common mode of failure of PCI. 252 Indeed, the comparison of surgical vs. PCI registries shows that presence of a chronic occlusion of one or more arteries in the PCI group as one of the most influential predictors of worse outcome, versus complete surgical revascularisation. 253, 254 Percutaneous coronary intervention of CTOs is technically difficult and needs acquaintance with advanced techniques and specialised equipment. The complexity of percutaneous treatment of CTOs is demonstrated by the comparatively low procedural success rates observed in CTOs (60-85%) compared with sub-total stenosis (>98%). 255, 256 Further, the success of percutaneous CTO recanalization has been enhanced by the introduction of DES, which has radically decreased re-stenosis rates, compared with BMS. [257] [258] [259] [260] Moreover, a recent systematic review demonstrated that DES use in CTO recanalization is showed lower target vessel revascularisation. 261 In addition, a surgical modality with the implantation of a distal bypass graft is an effective alternative, particularly with a left internal mammary artery on the left anterior descending and is technically simpler.
204,262
Refractory angina
Refractory angina is a clinical condition where angina cannot be controlled by medical therapy, angioplasty or revascularisation. To address refractory angina a number of new pharmacological and non-pharmacological modalities has been developed. Enhanced external counter pulsation (EECP) therapy [263] [264] [265] [266] 271 However, transmyocardial or percutaneous myocardial revascularisations have been restricted as they are found ineffective. 272 
Heart failure
Management of co-morbidities such as stable angina is a crucial component of the holistic care of heart failure (HF) patients. As already outlined, b-blockers are the preferred treatment to relieve angina in heart failure patients. Ivabradine is an effective alternative to b-blockers in patients with reduced ejection fraction and HR !70 bpm. As an add-on to beta-blockers, trimetazidine has been shown to exert some beneficial effect in patients with HF and angina. 170, 171, 273 It improves NYHA functional capacity, exercise duration and LV function in patients with reduced ejection fraction. The other alternatives in patients with reduced ejection fraction include CCBs (amlodipine), and nitrates. While the recent ESC 2016 HF guidelines have regarded the trimetazidine evidence as level 'A', Ranolazine and nicorandil have been given weak recommendations due to their uncertain safety profile. 274 The treatment algorithms were published in the NovemberDecember 2016 Issue of Indian Heart Journal as Executive Summary. Same are available in the next section. 275 
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